Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Tryngolza Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.82

    Tryngolza (olezarsen) Coverage

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.82 alerts

    Get alerted when Policy 05.05.82 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and continued coverage of Tryngolza (olezarsen) for adults with familial chylomicronemia syndrome or severe hypertriglyceridemia. Coverage requires applicable clinical criteria, documentation, dietary management, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyTryngolza (olezarsen) Coverage
    Policy CodePolicy 05.05.82
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionPrior authorization is required for Tryngolza coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial authorization period
    12 monthsContinuation authorization period
    ≥880 mg/dLFCS triglyceride threshold
    ≥500 mg/dLsHTG triglyceride threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≤20 g/day
    FCS dietary fat example
    80 mg or 50 mgMonthly dose by indication

    Coverage Criteria

    FCS — Initial Therapy

    Authorization of 6 months may be granted for treatment of familial chylomicronemia syndrome (FCS; type 1 hyperlipoproteinemia) when ALL of the following criteria are met:

    ALL of the following

    • Member is 18 years of age or older.
    • Member has genetic confirmation of pathogenic variants in FCS-causing genes (e.g., LPL, GPIHBP1, APOA5, APOC2, LMF1).
    • Member has an untreated fasting triglycerides (TG) level of ≥ 880 mg/dL (≥ 10 mmol/L).≥ 880 mg/dL (≥ 10 mmol/L)
    • Member is adhering to a very low-fat diet (e.g., ≤ 20 g of total fat per day).≤ 20 g total fat/day
    • Traditional lipid-lowering medications (e.g., statins, ezetimibe, niacin, fibrates, omega-3 fatty acids, PCSK9 inhibitors) have been ineffective in lowering fasting triglyceride level.
    • Member will not use Tryngolza in combination with Redemplo.

    Severe Hypertriglyceridemia — Initial Therapy

    Authorization of 6 months may be granted for treatment of severe hypertriglyceridemia (sHTG) when ALL of the following criteria are met:

    ALL of the following

    • Member is 18 years of age or older.
    • Member is stable on one or more lipid-lowering medications (e.g., statins, ezetimibe, niacin, fibrates, omega-3 fatty acids, PCSK9 inhibitors), or lipid-lowering medications have been ineffective in lowering fasting triglyceride level.
    • Member has persistently elevated fasting triglycerides (TG) level of ≥ 500 mg/dL (≥ 5.65 mmol/L) prior to initiating therapy with Tryngolza.≥ 500 mg/dL (≥ 5.65 mmol/L)
    • Modifiable secondary causes of hypertriglyceridemia have been addressed (i.e., medications and alcohol intake).

    FCS — Continuation Therapy

    Authorization of 12 months may be granted for continued treatment of FCS when BOTH of the following criteria are met:

    BOTH of the following

    • Member has demonstrated a positive clinical response with Tryngolza (e.g., reduction in TG level from baseline or reduction in episodes of acute pancreatitis).
    • Member is adhering to a very low-fat diet (e.g., ≤ 20 g of total fat per day).≤ 20 g total fat/day

    Severe Hypertriglyceridemia — Continuation Therapy

    Authorization of 12 months may be granted for continued treatment of sHTG when BOTH of the following criteria are met:

    BOTH of the following

    • Member has demonstrated a positive clinical response with Tryngolza (e.g., reduction in TG level from baseline or reduction in episodes of acute pancreatitis).
    • Tryngolza will be used concomitantly with dietary modifications (i.e., a low-fat diet).

    Tryngolza (olezarsen) must not be used in combination with Redemplo.

    Tryngolza (olezarsen) is not medically necessary for members who do not meet the applicable coverage criteria above.

    Members currently receiving Tryngolza as samples or through the manufacturer's patient assistance program must meet the criteria for initial approval. This ensures that members are treated equally regardless of their provider's ability to access medication samples.

    Clinical Thresholds and Dietary Requirements

    FCS fasting triglycerides
    ConditionFamilial chylomicronemia syndrome (FCS)
    Related terminologyType 1 hyperlipoproteinemia
    Genetic basisGenetic confirmation of pathogenic variants in FCS-causing genes is required
    Severe hypertriglyceridemia fasting triglycerides
    Threshold≥ 500 mg/dL
    Unit conversion≥ 5.65 mmol/L
    TimingPersistently elevated before initiating therapy

    Authorization and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Tryngolza is covered when used as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), or to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG), provided all applicable clinical criteria are met and no exclusions apply.

    • FDA-approved indication: FCS in adults.
    • FDA-approved indication: sHTG in adults.
    • The applicable FCS or sHTG criteria must be satisfied for approval.
    Prior Authorization

    FCS Initial Authorization

    Authorization may be granted for 6 months for treatment of FCS when all applicable initial criteria are met.

    • Member is at least 18 years old.
    • Genetic confirmation of pathogenic variants in FCS-causing genes, such as LPL, GPIHBP1, APOA5, APOC2, or LMF1.

    Therapy Background

    Tryngolza (olezarsen) is used as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome and to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

    Indication Definitions

    Familial chylomicronemia syndrome
    ConditionFamilial chylomicronemia syndrome (FCS)
    Related terminologyType 1 hyperlipoproteinemia
    DefinitionAn FCS-causing genetic disorder requiring genetic confirmation of pathogenic variants
    Severe hypertriglyceridemia
    ConditionSevere hypertriglyceridemia (sHTG)
    Triglyceride requirementPersistently elevated fasting triglycerides of ≥ 500 mg/dL (≥ 5.65 mmol/L)
    TimingRequirement applies before initiating Tryngolza therapy

    Initial Authorization Criteria

    FCS Initial Therapy — 6-Month Authorization

    Authorization of 6 months may be granted for FCS when ALL of the following criteria are met:

    All FCS initial therapy criteria

    • Age: Member is 18 years of age or older.≥18 years
    • Genetic confirmation: Member has genetic confirmation of pathogenic variants in FCS-causing genes.

      Examples include LPL, GPIHBP1, APOA5, APOC2, and LMF1.

    • Triglyceride level: Member has an untreated fasting triglyceride level of at least 880 mg/dL.≥880 mg/dL (≥10 mmol/L)

    Continuation Authorization Criteria

    FCS Continuation — 12-Month Authorization

    Authorization of 12 months may be granted for continued FCS treatment when BOTH of the following criteria are met:

    Both FCS continuation criteria

    • Clinical response: Member has demonstrated a positive clinical response with the requested medication.

      Examples include reduction in triglyceride level from baseline or reduction in episodes of acute pancreatitis.

    • Diet: Member is adhering to a very low-fat diet.Example: ≤20 g of total fat per day

    Severe Hypertriglyceridemia Continuation — 12-Month Authorization

    Authorization of 12 months may be granted for continued severe hypertriglyceridemia treatment when BOTH of the following criteria are met:

    Drug Quantity and Dosing Limits

    Tryngolza 80 mg injection quantity limit
    MedicationTryngolza (olezarsen) 80 mg injection
    Presentation80 mg/0.8 mL autoinjector pen
    Quantity limitOne autoinjector pen per 28 days
    Tryngolza 80 mg injection dosing
    MedicationTryngolza (olezarsen) 80 mg injection
    Dose and route80 mg injected subcutaneously once monthly
    PopulationAdults with familial chylomicronemia syndrome (FCS)
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyTryngolza (olezarsen) Coverage
    Policy CodePolicy 05.05.82
    Change TypeNo material clinical or coverage changes
    Effective DateOctober 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionPrior authorization is required for Tryngolza coverage.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Dietary RequirementsAuthorization and Submission RequirementsTherapy BackgroundIndication DefinitionsInitial Authorization CriteriaContinuation Authorization CriteriaDrug Quantity and Dosing Limits
    Tryngolza will be used concomitantly with dietary modifications (i.e., a low-fat diet).
  1. Member will not use Tryngolza in combination with Redemplo.
  2. FCS dietary fat intake
    Maximum total fat≤ 20 g per day
    Diet typeVery low-fat diet
    ApplicabilityRequired for FCS treatment and continued FCS treatment
  3. Untreated fasting triglycerides are ≥ 880 mg/dL (≥ 10 mmol/L).
  4. Member adheres to a very low-fat diet, such as ≤ 20 g of total fat per day.
  5. Traditional lipid-lowering medications have been ineffective in lowering fasting triglycerides.
  6. Tryngolza will not be used in combination with Redemplo.
  7. Prior Authorization

    Severe Hypertriglyceridemia Initial Authorization

    Authorization may be granted for 6 months for treatment of sHTG when all applicable initial criteria are met.

    • Member is at least 18 years old.
    • Member is stable on one or more lipid-lowering medications, or lipid-lowering medications have been ineffective in lowering fasting triglycerides.
    • Persistently elevated fasting triglycerides are ≥ 500 mg/dL (≥ 5.65 mmol/L) before Tryngolza is initiated.
    • Modifiable secondary causes of hypertriglyceridemia, including medications and alcohol intake, have been addressed.
    • Tryngolza will be used with dietary modifications, such as a low-fat diet.
    • Tryngolza will not be used in combination with Redemplo.
    Documentation Required

    Initial Request Documentation

    Include the following documentation with the initial prior authorization request.

    • Genetic test(s) confirming the diagnosis of FCS, if applicable.
    • Chart notes, medical records, or laboratory values documenting the fasting triglycerides (TG) level.
    Documentation Required

    Continuation Request Documentation

    Include documentation demonstrating a positive clinical response with continuation prior authorization requests.

    • Chart notes, medical records, or laboratory values documenting positive clinical response.
    Prior Authorization

    Prescriber Specialty

    The requested medication must be prescribed by or in consultation with one of the following specialist types.

    • Endocrinologist
    • Cardiologist
    • Lipid specialist
    • Gastroenterologist
    • Geneticist
    Denial Risk

    Criteria Not Met

    Tryngolza is considered not medically necessary when the member does not meet the applicable criteria set forth in the policy.

    • Ensure all applicable initial or continuation requirements are satisfied before submitting the request.
    Denial Risk

    Combination With Redemplo

    Concurrent use of Tryngolza with Redemplo does not meet the FCS or severe hypertriglyceridemia authorization criteria.

    • For both FCS and sHTG, the member must not use Tryngolza in combination with Redemplo.
    Denial Risk

    Samples or Patient Assistance

    Members currently receiving Tryngolza through samples or the manufacturer's patient assistance program must still meet the criteria for initial approval.

    • Access to samples or manufacturer assistance does not waive the initial approval requirements.
    • This requirement applies regardless of the provider's ability to access medication samples.
  8. Diet: Member is adhering to a very low-fat diet.Example: ≤20 g of total fat per day
  9. Prior lipid-lowering therapy: Traditional lipid-lowering medications have been ineffective in lowering the fasting triglyceride level.

    Examples include statins, ezetimibe, niacin, fibrates, omega-3 fatty acids, and PCSK9 inhibitors.

  10. No combination with Redemplo: Member will not use the requested medication in combination with Redemplo.No concomitant use
  11. Severe Hypertriglyceridemia Initial Therapy — 6-Month Authorization

    Authorization of 6 months may be granted for severe hypertriglyceridemia when ALL of the following criteria are met:

    All severe hypertriglyceridemia initial therapy criteria

    • Age: Member is 18 years of age or older.≥18 years
    • Lipid-lowering therapy: Member is stable on one or more lipid-lowering medications, or lipid-lowering medications have been ineffective in lowering the fasting triglyceride level.

      Examples include statins, ezetimibe, niacin, fibrates, omega-3 fatty acids, and PCSK9 inhibitors.

    • Triglyceride level: Member has persistently elevated fasting triglycerides before initiating therapy with the requested medication.≥500 mg/dL (≥5.65 mmol/L)
    • Secondary causes: Modifiable secondary causes of hypertriglyceridemia have been addressed.

      Secondary causes include medications and alcohol intake.

    • Diet: The requested medication will be used concomitantly with dietary modifications.Low-fat diet
    • No combination with Redemplo: Member will not use the requested medication in combination with Redemplo.No concomitant use

    Both severe hypertriglyceridemia continuation criteria

    • Clinical response: Member has demonstrated a positive clinical response with the requested medication.

      Examples include reduction in triglyceride level from baseline or reduction in episodes of acute pancreatitis.

    • Diet: The requested medication will be used concomitantly with dietary modifications.Low-fat diet
    Tryngolza 50 mg injection quantity limit
    MedicationTryngolza (olezarsen) 50 mg injection
    Presentation50 mg/0.8 mL autoinjector pen
    Quantity limitOne autoinjector pen per 28 days
    Tryngolza 50 mg injection dosing
    MedicationTryngolza (olezarsen) 50 mg injection
    Dose and route50 mg injected subcutaneously once monthly
    PopulationAdults with severe hypertriglyceridemia (sHTG)